Core Viewpoint - Kanglong Chemical announced the approval of a proposal to issue new H-shares based on general authorization during the 18th meeting of its third board of directors [1] Group 1 - The board meeting was held on January 15 [1] - The proposal aims to enhance the company's capital structure and support future growth [1]

Group 1 - The company, 康龙化成, experienced a significant decline in its H-shares, dropping by 7.7% [1] - The company plans to issue new H-shares at a discount of 8.5% [1]

Group 1 - The company, 康龙化成 (3759.HK), experienced a significant intraday drop of nearly 8% to HKD 23.02 [1] - The company announced a placement of approximately 58 million new H-shares at a price of HKD 22.82 per share, representing an 8.5% discount to the closing price on Wednesday [1] - The placement shares will account for 3.19% of the total issued shares post-expansion, with the company aiming to raise approximately HKD 1.33 billion for project construction, working capital, and repayment of bank loans and other borrowings [1] Group 2 - The company recently released an earnings forecast, projecting a net profit attributable to shareholders for 2025 to be between RMB 1.614 billion and RMB 1.686 billion, reflecting a year-on-year decline of 6% to 10% [1] - During the reporting period, the company's operating revenue is expected to grow by 13% to 16% year-on-year, while the net profit after excluding non-recurring gains and losses is anticipated to increase by 36% to 41% year-on-year [1]

Core Viewpoint - 康龙化成 (03759) experienced a decline of over 7%, currently trading at 23.18 HKD, with a transaction volume of 27.84 million HKD [1] Group 1: Company Announcement - 康龙化成 announced a proposed placement of approximately 58.44 million new H-shares, representing about 3.19% of the company's enlarged total issued shares and about 16.57% of the total issued H-shares [1] - The placement price is set at 22.82 HKD per share, reflecting a discount of approximately 8.5% compared to the closing price on January 14 [1] Group 2: Use of Proceeds - The company expects to raise approximately 1.334 billion HKD in total proceeds, with a net amount of about 1.319 billion HKD from the placement [1] - Approximately 70% of the proceeds will be allocated to project construction, aimed at enhancing laboratory service facilities, drug process development, and production capacity [1] - About 10% of the proceeds will be used to repay bank loans and other borrowings to optimize the capital structure, while the remaining 20% will be allocated for working capital and other general purposes [1]

Core Viewpoint - 康龙化成 (300759) announced a placement of approximately 58.44 million new H-shares, leading to a decline of over 7% in its stock price, indicating market reaction to the dilution of shares and the pricing of the placement [1] Group 1: Share Placement Details - The share placement represents about 3.19% of the company's expanded total issued shares and approximately 16.57% of the total issued H-shares [1] - The placement price is set at HKD 22.82 per share, which reflects an 8.5% discount compared to the closing price on January 14 [1] - The expected total gross proceeds from the placement are approximately HKD 1.334 billion, with net proceeds estimated at HKD 1.319 billion [1] Group 2: Use of Proceeds - Approximately 70% of the proceeds will be allocated for project construction to enhance laboratory service facilities, drug process development, and production capacity [1] - About 10% of the funds will be used to repay bank loans and other borrowings to optimize the capital structure [1] - The remaining 20% will be utilized to supplement working capital and for other general purposes [1]

格隆汇1月15日丨康龙化成(300759.SZ)公布，2026年1月14日，公司与高盛(亚洲)有限责任公司及香港上 海汇丰银行有限公司(以下统称"配售代理")签署了配售协议。根据配售协议，公司同意委任配售代理而 配售代理各自同意(而非共同，亦非共同及个别)出任公司代理，并尽力促使若干承配人按照配售协议所 载条款及条件，按每股配售股份22.82港元(以下称"配售价")认购公司根据一般发行授权拟发行的 58,440,762股新H股(以下称"配售股份")。 假设配售股份获全数认购，配售所得款项总额预期约为1,333.6百万港元。配售所得款项净额预期约为 1,318.7百万港元，每股配售股份的净价约为22.56港元，公司拟将所得款项净额用作以下用途：(1)约 70%将用于公司的项目建设，以加强我们实验室服务设施、药物工艺开发及生产设施的能力及产能；(2) 约10%将用于偿还银行贷款及其他借款以优化公司资本结构；(3)约20%将用于补充营运资金及其他一般 企业用途。上述募集资金用途届时会根据最终的发行规模进行相应调整。 配售股份数目分别占：(a)截至本公告日期现有已发行H股总数及现有已发行股份总数约19.86%及 3. ...

董事会认为，公司是一家领先的全流程一体化医药研发生产服务平台，业务遍及全球，致力于进一步巩 固服务能力，加速全球药物创新。进行本次发行事项将进一步加强本公司的资金实力，把握行业机遇， 助力产能投入与业务拓展。本次发行也将为公司引入国际优质机构投资者群体，进一步扩大股东基础， 并有望显着增强H股的交易流动性，有助于加强公司的国际资本运作能力。另外，通过偿还部分现有债 务，公司的资本结构将得到进一步优化。此次发行将支持公司继续保持在医药研发服务领域的领先地 位，符合公司的长期发展战略。 配售股份数目分别占：(a)截至本公告日期现有已发行H股总数及现有已发行股份总数约19.86%及 3.30%；及(b)假设于本公告日期至完成期间配售股份均获认购，且除公司发行配售股份外，已发行股份 总数无其他变动，则配售完成后，配售股份数目分别占经配售股份发行扩大的已发行H股总数及已发行 股份总数约16.57%及3.19%。 假设配售股份获全数认购，配售所得款项总额预期约为1,333.6百万港元。配售所得款项净额预期约为 1,318.7百万港元，每股配售股份的净价约为22.56港元，公司拟将所得款项净额用作以下用途：(1)约 70% ...

康龙化成在香港交易所公告称，同意以每股22.82港元的价格配售约5800万股新H股。配售价格较周三收 盘价折让约8.5%。配售股份占扩大后已发行股份总数的3.19%。公司将通过此次配售筹资约13.3亿港 元，所得款项将用于项目建设、营运资金、偿还银行贷款及其他借款。高盛和汇丰是联席全球协调人。 ...

2026年1月14日(交易时段后)，公司与高盛(亚洲)有限责任公司及香港上海汇丰银行有限公司签署了配售 协议。根据配售协议，公司同意委任配售代理而配售代理各自同意(而非共同，亦非共同及个别)出任公 司代理，并尽力促使若干承配人按照配售协议所载条款及条件，按每股配售股份22.82港元认购公司根 据一般发行授权拟发行的5844.0762万股新H股。 康龙化成（300759）(300759.SZ)公告，公司拟根据2024年年度股东大会审议通过的《关于股东大会给 予董事会增发公司H股股份一般性授权的议案》项下股东大会对董事会增发H股股份的授权，新增发行 境外上市外资股(H股)。 ...

Group 1 - The company, Kanglong Chemical (300759.SZ), plans to issue new H-shares based on the authorization granted by the shareholders' meeting for the board to increase the issuance of H-shares [1] - On January 14, 2026, the company signed a placement agreement with Goldman Sachs (Asia) LLC and HSBC Hong Kong, appointing them as placement agents [1] - The company intends to issue 58,440,762 new H-shares at a subscription price of HKD 22.82 per share according to the terms of the placement agreement [1]